Interleukin Genetics Inc (ILI) Financial Statements (2024 and earlier)

Company Profile

Business Address 135 BEAVER ST
WATHAM, MA 02452
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,6574,3441,2742,8924,7066,271
Cash and cash equivalents2,6574,3441,2742,8924,7066,271
Receivables106317532858646
Inventory, net of allowances, customer advances and progress billings73788891125159
Inventory73788891125159
Prepaid expense435469622670779532
Total current assets:3,2715,2092,0373,9385,6967,007
Noncurrent Assets
Property, plant and equipment511537545599644659
Intangible assets, net (including goodwill)2534425159138
Intangible assets, net (excluding goodwill)2534425159138
Other noncurrent assets282828289399
Total noncurrent assets:565599615677796896
TOTAL ASSETS:3,8365,8082,6524,6166,4927,903
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7441,0181,3007339061,032
Accounts payable506427770366408576
Accrued liabilities238592530367498455
Debt2,3052,0002,0001,8331,333 
Deferred revenue and credits2,5032,5292,6862,8753,2392,926
Total current liabilities:5,5515,5475,9865,4415,4783,957
Noncurrent Liabilities
Long-term debt and lease obligation1,1301,5972,2902,9333,4754,791
Long-term debt, excluding current maturities1,1301,5972,2902,9333,4754,791
Total noncurrent liabilities:1,1301,5972,2902,9333,4754,791
Total liabilities:6,6817,1458,2758,3748,9538,748
Equity
Equity, attributable to parent(2,846)(1,337)(5,624)(3,759)(2,461)(845)
Common stock229229173173173173
Additional paid in capital133,327132,994126,796126,575126,354126,108
Accumulated deficit(136,402)(134,560)(132,593)(130,506)(128,988)(127,126)
Total equity:(2,846)(1,337)(5,624)(3,759)(2,461)(845)
TOTAL LIABILITIES AND EQUITY:3,8365,8082,6524,6166,4927,903

Income Statement (P&L) ($ in thousands)

3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
Revenues228734590961366296
Revenue, net151269349262234249
Cost of revenue(276)(443)(355)(527)(428)(323)
Gross profit:(49)291235434(63)(27)
Operating expenses(1,508)(2,104)(2,174)(1,800)(1,646)(1,845)
Operating loss:(1,556)(1,813)(1,939)(1,366)(1,709)(1,872)
Nonoperating expense(286)(154)(148)(152)(153)(153)
Interest and debt expense(448)(68)(110)(114)(153)(153)
Other undisclosed income from continuing operations before equity method investments, income taxes44868110114153153
Loss from continuing operations:(1,843)(1,967)(2,087)(1,518)(1,863)(2,026)
Loss before gain (loss) on sale of properties:(1,843)(1,967)(2,087)(1,518)(1,863)(2,026)
Net loss available to common stockholders, diluted:(1,843)(1,967)(2,087)(1,518)(1,863)(2,026)

Comprehensive Income ($ in thousands)

3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
Net loss:(1,843)(1,967)(2,087)(1,518)(1,863)(2,026)
Comprehensive loss, net of tax, attributable to parent:(1,843)(1,967)(2,087)(1,518)(1,863)(2,026)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: